ReviewMicroorganisms2024
Changes in the Gastrointestinal Microbiota Induced by Proton Pump Inhibitors-A Review of Findings from Experimental Trials.
Review in Microorganisms, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 18 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
18 citing papers in PubMed, 1 synthesis or guideline pooled it.
- Medication Causes and Treatment of Delirium in Patients With and Without Dementia.Brain and behavior · 2025Pooled it
- Evolution of proton pump inhibitor research in reflux esophagitis: a Web of Science-based global bibliometric assessment [1990-2026].Journal of thoracic disease · 2026Article
- MyBioScope: a new frontier in gut microbiome and health research.Bioresources and bioprocessing · 2026Article
- Rethinking Long-Term PPI Therapy in GERD: A Narrative Review from a Microbial Ecology Perspective Beyond Acid Suppression.Pharmaceuticals (Basel, Switzerland) · 2026Review
- Gut Microbial Variations Associated With Proton Pump Inhibitor Use in the Boston Puerto Rican Health Study.Pharmacology research & perspectives · 2026Article
- Proton pump inhibitor exposure modulates functional and transcriptional responses inFrontiers in cellular and infection microbiology · 2026Article
- Multi-omics analysis identifies gut microbiota-glutamine axis contributing to the pathogenesis of reflux esophagitis.Frontiers in microbiology · 2026Article
- Research advances on gut microbiota dysbiosis and chronic liver diseases: a review.Frontiers in medicine · 2026Review
- A review of current evidence and perspectives on the mechanisms and clinical significance of hypoxia-induced remodeling of the gastric microbiota-metabolism axis.Frontiers in microbiology · 2026Review
- Comparative gastric microbiota profiles in non-ulcer dyspepsia and peptic ulcer patients.BMC microbiology · 2025Article
- Garvicin Q-producing Lactococcus garvieae LG3092: its role in mitigating dysbiosis and H. pylori-associated gastritis.NPJ biofilms and microbiomes · 2025Article
- The Use of Proton Pump Inhibitors Among Adults in Norway-A Nationwide Drug Utilization Study.Pharmacology research & perspectives · 2025Article
- Proton Pump Inhibitor Use in Older Adult Patients with Multiple Chronic Conditions: Clinical Risks and Best Practices.Journal of clinical medicine · 2025Review
- Review
- Endoscopic anti-reflux mucosal resection for patients with gastroesophageal reflux disease: Clinical efficacy and impact on gut microbiota.World journal of gastrointestinal surgery · 2025Article
- Metaproteomics in the One Health framework for unraveling microbial effectors in microbiomes.Microbiome · 2025Review
- Why think twice before prescribing proton pump inhibitors.European journal of pediatrics · 2025Review
- Hyaluronic acid and chondroitin sulfate-based medical devices: formulations, esophageal mucosal protection, and their place in the management of GERD.Therapeutic advances in gastroenterology · 2025Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
The use of proton pump inhibitors (PPIs) has increased considerably in many Western countries, and there is concern that numerous conditions and diseases associated with PPI use may be adverse events. The main function of gastric acid is to defend the organism against orally ingested microorganisms, and there is also concern that alterations not only in the gastric microbiome but also the downstream intestinal microbiome may increase the risk of disease or alter the course of preexisting disease. The current study is a systematic review of the available evidence from experimental trials investigating the effects of PPIs on the gastrointestinal microbiota by next-generation sequencing. Thirteen studies were identified. The effects of PPIs were seen on alterations in diversity and richness in some of the studies, while a larger proportion of the studies detected alterations at various taxonomic levels. The general finding was that PPI use caused an increase in bacteria normally found in the oral microbiota in both the upper and lower GI tract. The most consistent taxonomic alterations seemed to be increases in oral flora along the axis Streptococcaceae and
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.